Daiichi Sankyo was selected and awarded the second consecutive year as "the SX ( Sustainability Transformation) Brands", which is initiated by Ministry of Economy, Trade and Industry and Tokyo Stock Exchange, Inc.
　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　
Under our 2030 Vision, the Daiichi Sankyo Group aims to become an innovative global healthcare company contributing to the development of a sustainable society, and is actively promoting ESG management.

In this year’s selection, we were recognized for clearly identifying the gap between our current state and our vision, and for integrating business strategy, human capital strategy, digital transformation (DX), and capital strategy into a cohesive overall strategy. Our steady progress in initiatives such as intellectual property strategy and the divestment of non-core assets also contributed to our evaluation. Furthermore, we were highly rated for our well-established systems in governance and stakeholder engagement.
In particular, our sustainability management—deeply rooted in our core business—was praised for addressing the global social issue of oncology drug discovery through our strengths in science and technology, resulting in the consistent achievement of strong business performance.
Efforts such as the strengthening of human capital, which serves as the foundation of value creation, and continuous investment in research and development, were also recognized as distinctive and noteworthy features.

■What is SX brand?

SX (Sustainability Transformation) means promoting long-term and sustainable creation of corporate value by engaging in constructive dialogues with investors and other parties, incorporating society's sustainability issues and needs into their own growth, and making necessary management and business reforms. These enterprises will be selected and awarded as the Sustainability Transformation Brands.

For more information on "SX Brands", please click here.